Association between prehospital shock index variation and 28-day mortality among patients with septic shock

Romain Jouffroy1,2,3,4,5*, Basile Gilbert6, Léa Thomas7, Emmanuel Bloch-Laine8, Patrick Ecollan9, Josiane Boularan10, Vincent Bounes6, Benoît Vivien5 and Papa-Ngalgou Gueye11

Abstract

Purpose: Septic shock (SS) hyperdynamic phase is characterized by tachycardia and low-blood pressure reflecting the relative hypovolemia. Shock index (SI), the ratio between heart rate and systolic blood pressure, is a simple objective tool, usable for SS prognosis assessment.

This study aims to evaluate the relationship between prehospital SI variation and 28-day mortality of SS patients initially cared for in prehospital setting by a mobile intensive care unit (mICU).

Methods: From April 6th, 2016 to December 31st, 2020, 406 patients with SS requiring prehospital mICU were retrospectively analyzed. Initial SI, i.e. first measurement after mICU arrival to the scene, and final SI, i.e. last measurement of the prehospital stage, were used to calculate delta SI (initial SI—final SI) and to define positive and negative delta SI. A survival analysis after propensity score matching compared the 28-day mortality of SS patients with positive/negative delta SI.

Results: The main suspected origins of infection were pulmonary (42%), digestive (25%) and urinary (17%). The 28-day overall mortality reached 29%.

Cox regression analysis revealed a significant association between 28-day mortality and delta SI. A negative delta SI was associated with an increase in mortality (adjusted hazard ratio (HRa) of 1.88 [1.07–3.31] (p = 0.03)), whereas a positive delta SI was associated with a mortality decrease (HRa = 0.53 [0.30–0.94] (p < 10−3)).

Conclusion: Prehospital hemodynamic delta SI among SS patients cared for by a mICU is associated with 28-day mortality. A negative prehospital delta SI could help physicians to identify SS with higher risk of 28-day mortality.

Keywords: Septic shock, Prehospital setting, Mortality, Shock index, Variation

Introduction

Every year, sepsis affects more than 30 million people worldwide [1–3] leading to around 11 million deaths [3]. Despite progress in the prevention, diagnosis and care, sepsis related mortality rate still ranges from 10 to 20% and from 50 to 60% for septic shock [4–6].

The World Health Assembly, the World Health Organization and the “SEPSIS-3” conference emphasize prevention, early recognition, severity assessment and treatment of septic patients to decrease mortality [7, 8]. Early recognition of septic shock (SS) is the first step prior diagnosis, severity assessment and treatment implementation [7], in both prehospital and in-hospital setting [3, 6]. In the prehospital setting, severity assessment influences...
the orientation to the appropriate ward, i.e. emergency department (ED) for less severe patients or intensive care unit (ICU) for the most severe patients [9]. In the prehospital setting, the early recognition and prognostication of sepsis remains a daily challenge, most of the time based on clinical examination [10]. Among tools that can be used to recognize and to assess the severity, we previously reported that skin mottling score and capillary refill time, and initial prehospital shock index (SI), ratio between heart rate and systolic blood pressure [11], normal range from 0.5 to 0.7 in healthy adult [11], are associated with increased mortality of patients with SS initially cared for in the prehospital setting [12, 13].

By similarity with the relative blood lactate clearance, which is a prognostic tool usable in the pre and in-hospital setting for sepsis severity assessment [14, 15], for treatment effect assessment [7, 15–18] and to guide sepsis resuscitation [7, 19, 20], we investigated in this study the association between prehospital SI variation and 28-day mortality of patients presenting with septic shock initially cared for in prehospital setting by a mobile intensive care unit (mICU). The aim of the study was to show that, in the same way as lactate clearance, is an indirect tool for treatment effect assessment [7, 21], the change in SI is a clinical tool allowing of treatment effect assessment.

**Methods**

**Background**

As previously reported [22], the French prehospital emergency medical service (EMS) is based on the SAMU (Urgent Medical Aid Service), a public health control organization, which provides medical response to prehospital emergency situations. The SAMU is made up of emergency physicians and assistants answer calls who respond to the patients’ complaints [23]. In the case of life-threatening emergencies, a mICU, the SMUR (Mobile Emergency and Resuscitation Service) staffed with an emergency physician and equipped with medical devices and drugs allowing initial management of major organ deficiency, is dispatched to the scene [24] in order to provide out-of-hospital treatment and transport to definitive in-hospital care, either the ED or the ICU.

**Patients**

From April 06th, 2016 to December 31st, 2020, septic shock patients to the 2012 sepsis-2 conference [25] cared for by a mICU teams of 7 hospital centres (Necker-Enfants Malades Hospital, Lariboisière Hospital, La Pitié-Salpêtrière Hospital, Hôtel Dieu Hospital, APHP, Paris – France; The Paris Fire Brigade Paris, – France; the Toulouse University Health Centre, Toulouse – France and the Castres Hospital, Castres – France), were retrospectively analyzed. Septic shock diagnosis was established after hospital admission and patient identification based on medical hospital reports. In the prehospital setting, septic shock diagnosis was presumed on clinical history, clinical signs and lactate measurement of available according to the sepsis-2 conference [25].

Patients younger than 18 years, and/or pregnant, and/or at the terminal stage of any comorbidity and/or with guardianship or curatorship were not included in this study [26]. One-hundred and fourteen among the 406 patients included in this study were previously retrospectively analyzed [13].

Patients’ demographic characteristics (age, weight, height, and gender), supposed prehospital origin of sepsis, initial prehospital (i.e., the first mICU contact), and final prehospital (i.e., at the end of prehospital stage) vital sign values (systolic (SBP), diastolic (DBP) and mean arterial pressure (MAP)) were measured with a non-invasive automated devices in all centres. Heart rate (HR), pulse oximetry (SpO2), respiratory rate (RR), temperature and Glasgow coma scale (GCS)), plasma blood glucose level, duration of prehospital care, and prehospital treatments delivered (antibiotic therapy type and dose, fluid volume expansion type and dose, as well as catecholamine type and dose), were collected from mICU prehospital medical reports. Previous underlying comorbidities (chronic cardiac failure, chronic renal failure, chronic obstructive pulmonary disease, diabetes mellitus, and history of cancer) were also collected [27].

Initial SI corresponds to the SI measured by mICU after their arrival to the scene, whereas final SI corresponds to the SI measured just prior hospital arrival. Delta SI represents the difference between initial SI and final SI. Delta SI was encoded as a categorical variable (0 for negative delta SI or 1 for positive delta SI).

Initial blood lactate is the blood lactate value measured after mICU arrival to the scene and final blood lactate the value measured just prior hospital arrival using a point of care medical device (StatStrip® Lactates, Nova Biomedical, Waltham, MA, USA) with correct comparability and transferability according to the central laboratory analyzers [28]. Delta lactate was estimated by the following equation: (initial blood lactate—final blood lactate) / prehospital duration (mmol.L⁻¹.minutes⁻¹). Delta lactate was encoded as a categorical variable (0 for negative delta lactate or 1 for positive delta lactate).

The in-hospital length of stay (LOS) and the 28-day mortality were retrieved from medical reports in case of death in hospital or by phone call when the patient was discharged from the hospital. The Sequential Organ Failure Assessment (SOFA) score [29] and the Simplified Acute Physiology Score (SAPS 2) [30] were calculated 24 h after ICU admission.
Table 1  Population characteristics. Results were expressed as mean and standard deviation for quantitative parameters (normal distribution), as median and interquartile range for quantitative parameters (non-gaussian distribution) and, as absolute value and percentage for qualitative parameters. P-value corresponds to the comparison between deceased and living patients.

| Demographics                      | Overall population (n = 406) | Living (n = 290) | Deceased (n = 116) | p value |
|------------------------------------|-----------------------------|-----------------|-------------------|--------|
| Age (years)                        | 69 ± 15                     | 67 ± 16         | 72 ± 14           | 0.005  |
| Hypertension (41%)                 | 166 (41%)                   | 117 (40%)       | 49 (42%)          | 0.726  |
| Chronic cardiac failure (17%)      | 69 (17%)                    | 44 (15%)        | 25 (22%)          | 0.124  |
| Diabetes Mellitus (26%)            | 106 (26%)                   | 83 (29%)        | 23 (20%)          | 0.07   |
| Cancer history (35%)               | 144 (35%)                   | 95 (33%)        | 49 (42%)          | 0.072  |
| COPD (14%)                         | 55 (14%)                    | 34 (12%)        | 21 (18%)          | 0.092  |
| Chronic Renal Failure (13%)        | 52 (13%)                    | 32 (11%)        | 20 (17%)          | 0.093  |

| Prehospital initial values         |                            |                 |                   |        |
|------------------------------------|-----------------------------|-----------------|-------------------|--------|
| Initial SBP (mmHg)                 | 102 ± 43                    | 103 ± 47        | 97 ± 27           | 0.193  |
| Initial DBP (mmHg)                 | 59 ± 20                     | 60 ± 21         | 58 ± 19           | 0.240  |
| Initial MBP (mmHg)                 | 72 ± 22                     | 73 ± 23         | 70 ± 20           | 0.211  |
| Initial HR (beats.min⁻¹)           | 112 ± 28                    | 112 ± 28        | 112 ± 30          | 0.974  |
| Initial SI                         | 1.2 ± 0.5                   | 1.2 ± 0.5       | 1.2 ± 0.5         | 0.354  |
| Initial RR (movements.min⁻¹)       | 30 [22-38]                  | 28 [22-36]      | 32 [25-39]        | 0.088  |
| Initial pulse oximetry (%)         | 93 [87 – 96]                | 94 [88 – 97]    | 91 [83 – 95]      | 0.012  |
| Initial body core temperature (°C) | 38.5 [37.0 – 39.3]          | 38.6 [37.1 – 39.5] | 38.2 [35.8 – 39.0] | 0.011  |
| Initial Glasgow coma scale         | 15 [13-15]                  | 15 [14-15]      | 15 [12-15]        | 0.018  |
| Initial blood lactate (mmol.l⁻¹)   | 6.2 ± 3.7                   | 5.8 ± 3.5       | 6.9 ± 4.0         | 0.059  |
| Fluid expansion (ml)               | 625 [500 – 1200]            | 675 [500 – 1000] | 500 [500 – 1000]  | 0.762  |
| Fluid expansion / body weight (ml.kg⁻¹) | 15 ± 10                   | 15 ± 10         | 14 ± 10           | 0.812  |
| Norepinephrine administration (%)  | 100 (25%)                   | 83 (29%)        | 32 (28%)          | 0.357  |
| Norepinephrine dose (mg.h⁻¹)       | 1.0 [0.5 – 2.0]             | 1.0 [0.7 – 2.0] | 1.0 [0.7 – 2.0]   | 0.668  |
| Prehospital AB administration (%)  | 114 (28%)                   | 83 (29%)        | 31 (27%)          | 0.701  |
| Prehospital duration (min)         | 65 ± 32                     | 64 ± 32         | 66 ± 31           | 0.373  |

| Prehospital final values           |                            |                 |                   |        |
|------------------------------------|-----------------------------|-----------------|-------------------|--------|
| Final SBP (mmHg)                   | 103 ± 26                    | 104 ± 26        | 100 ± 28          | 0.147  |
| Final DBP (mmHg)                   | 60 ± 18                     | 60 ± 18         | 58 ± 20           | 0.360  |
| Final MBP (mmHg)                   | 74 ± 20                     | 74 ± 19         | 72 ± 22           | 0.242  |
| Final HR (beats.min⁻¹)             | 106 ± 25                    | 107 ± 24        | 109 ± 27          | 0.267  |
| Final SI                           | 1.1 ± 0.7                   | 1.1 ± 0.7       | 1.1 ± 0.4         | 0.595  |
| Delta SI                           | 0.1 ± 0.7                   | 0.01 ± 0.8      | 0.01 ± 0.5        | 0.886  |
| Positive delta SI (%)              | 248 (61%)                   | 183 (63%)       | 65 (56%)          | 0.188  |
| Negative delta SI (%)              | 158 (39%)                   | 107 (37%)       | 31 (44%)          | 0.188  |
| Final RR (movements.min⁻¹)         | 25 [20-33]                  | 24 [18-30]      | 29 [22-35]        | 0.002  |
| Final pulse oximetry (%)           | 97 [94 – 99]                | 97 [95 – 99]    | 96 [92 – 98]      | 0.004  |
| Final body core temperature (°C)   | 38.2 [37.0 – 39.0]          | 38.3 [37.2 – 39.0] | 37.8 [35.9 – 38.9] | 0.004  |
| Final Glasgow coma scale           | 15 [14-15]                  | 15 [14-15]      | 15 [13-15]        | 0.001  |
| Final blood lactate (mmol.l⁻¹)     | 4.5 ± 3.6                   | 3.7 ± 3.0       | 6.1 ± 4.3         | <10⁻³  |
| Delta blood lactate (mmol.l⁻¹)     | 1.2 ± 2.8                   | 1.6 ± 2.9       | 0.4 ± 2.5         | 0.01   |
| Positive delta blood lactate (%)   | 115 (28%)                   | 80 (28%)        | 35 (30%)          | 0.161  |
| Negative delta blood lactate (%)   | 54 (13%)                    | 32 (11%)        | 22 (19%)          | 0.217  |

| Hospital parameters                |                            |                 |                   |        |
|------------------------------------|-----------------------------|-----------------|-------------------|--------|
| SOFA score                         | 7 [3-10]                    | 6 [3-9]         | 9 [6-12]          | <10⁻³  |
| SAPS2 score                        | 58 ± 22                     | 52 ± 19         | 70 ± 22           | <10⁻³  |
| In-ICU length of stay (days)       | 5 [2-9]                     | 5 [2-9]         | 4 [2-8]           | 0.099  |
| In-hospital length of stay (days)  | 12 [7-20]                   | 15 [9-24]       | 4 [2-13]          | <10⁻³  |
In order to minimize the bias in data abstraction [31], data collection was performed by a single investigator (RJ) using a standardized abstraction template.

Ethical considerations
The study was approved by the French Society of Anesthesia and Intensive Care ethics committee on December 12th, 2017 (Ref number: IRB 00,010,254–2017-026). The French Society of Anesthesia and Intensive Care ethics committee waived the need of informed consent.

Statistical Analysis
Results are expressed as mean with standard deviation for quantitative parameters with a normal distribution, as median with interquartile range [Q1-Q3] for parameters with a non-Gaussian distribution, and as absolute value and percentage for qualitative parameters.

The primary outcome was the 28-day mortality rate.

Statistical analysis was a priori decided, and the statistical analysis plan developed prior to analysis.

Univariate and multivariate analyses were performed to evaluate the relationship between each covariate and the 28-day mortality rate.

To reduce the effect of confounders on 28-day mortality and on delta SI, a propensity score matching was used to balance the differences in baseline characteristics between patients with positive SI and those with negative SI [32]. The propensity score was estimated using logistic regression based on potential confounders on 28-day mortality and on SI variation: age, prehospital duration, prehospital catecholamine infusion [26], prehospital fluid expansion [26], hypertension [26], chronic cardiac failure, chronic renal failure, chronic obstructive pulmonary disease, AIDS, antibiotic therapy, min minutes, delta SI = Initial SI-Final SI, negative delta SI = Initial SI-Final SI < 0, positive delta SI = Initial SI-Final SI > 0, delta Lactate = Lactate SI-Lactate SI, negative delta Lactate = Initial Lactate-Final Lactate < 0, positive delta Lactate = Initial Lactate-Final Lactate > 0.

Table 1 (continued)

| Presumed septic shock origins | Overall population (n = 406) | Living (n = 290) | Deceased (n = 116) | p value |
|-------------------------------|-----------------------------|-----------------|-------------------|---------|
| Pulmonary                     | 170 (42%)                   | 111 (38%)       | 59 (51%)          | 0.021   |
| Digestive                     | 102 (25%)                   | 70 (24%)        | 32 (28%)          | 0.470   |
| Urinary                       | 67 (17%)                    | 56 (19%)        | 11 (9%)           | 0.018   |
| Cutaneous                     | 28 (7%)                     | 23 (8%)         | 5 (4%)            | 0.200   |
| Meningeal                     | 9 (2.5%)                    | 7 (2%)          | 2 (2%)            | 0.671   |
| Gynaecological                | 3 (0.5%)                    | 3 (100%)        | 0 (0%)            | 0.986   |
| Eyes nose throat              | 2 (0.5%)                    | 1 (50%)         | 1 (50%)           | 0.516   |
| Endocarditis                  | 2 (0.5%)                    | 2 (100%)        | 0 (0%)            | 0.983   |
| Unknown                       | 23 (5%)                     | 17 (6%)         | 6 (5%)            | 0.786   |

Values in bold indicate a p-value < 0.05 between living and deceased patients

SMD

\[
SMD = 100 \times \frac{|x(\text{cases}) - x(\text{controls})|}{\sqrt{(scases)^2 + s(controls)^2}}
\]

where x denotes the mean or proportion for binary variables and classes of categorical variables et s the variance.

Thereafter, in the matched sample, baseline characteristics were compared between cases (patients with negative SI) and controls (patients with positive SI) by paired tests.

Finally, in the propensity score–matched cohort, a survival analysis using Cox proportional hazards regression was used to compare the 28-day mortality of patients according to (i) the positive or negative delta SI, and (ii) the positive or negative delta lactate. Proportional hazards assumption was verified for each Cox model variable by Kaplan Meier curves and the log-rank test.
Table 2 Comparison between patients with a positive and a negative delta SI. Results were expressed as mean and standard deviation for quantitative parameters (normal distribution), as median and interquartile range for quantitative parameters (non-gaussian distribution) and, as absolute value and percentage for qualitative parameters. P-value corresponds to the comparison between deceased and living patients.

| Demographics                  | Positive SI (n = 249) | Negative SI (n = 157) | p value |
|-------------------------------|-----------------------|-----------------------|---------|
| Age (years)                   | 70±15                 | 68±16                 | 0.247   |
| Hypertension                  | 102 (41%)             | 64 (41%)              | 0.968   |
| Chronic cardiac failure       | 33 (13%)              | 36 (23%)              | 0.012   |
| Diabetes Mellitus             | 68 (27%)              | 38 (24%)              | 0.488   |
| Cancer history                | 88 (35%)              | 56 (36%)              | 0.946   |
| COPD                          | 30 (12%)              | 25 (16%)              | 0.268   |
| Chronic Renal Failure         | 32 (13%)              | 20 (13%)              | 0.974   |

| Prehospital initial values    |                       |                       |         |
|-------------------------------|-----------------------|-----------------------|---------|
| Initial SBP (mmHg)            | 91±26                 | 115±31                | <10^{-3}|
| Initial DBP (mmHg)            | 53±17                 | 69±21                 | <10^{-3}|
| Initial MBP (mmHg)            | 65±19                 | 83±22                 | <10^{-3}|
| Initial HR (beats.min⁻¹)      | 117±28                | 106±27                | 10^{-4} |
| Initial RR (movements.min⁻¹)  | 28 [22-36]            | 31 [24-40]            | 0.135   |
| Initial pulse oximetry (%)    | 93 [88 – 97]          | 92 [84 – 96]          | 0.139   |
| Initial body core temperature (°C) | 38.5 [37.0 – 39.4] | 38.4 [37.0 – 39.3] | 0.707   |
| Initial Glasgow coma scale    | 15 [13-15]            | 15 [14-15]            | 0.168   |
| Initial blood lactate (mmol.l⁻¹) | 6.0±3.6              | 6.8±4.0               | 0.212   |
| Fluid expansion (ml)          | 750 [500 – 1250]      | 500 [500 – 1000]      | <10^{-3}|
| Fluid expansion / body weight (ml.kg⁻¹) | 16±11               | 12±7                  | 10^{-4} |
| Norepinephrine administration | 75 (30%)              | 25 (16%)              | 10^{-3} |
| Norepinephrine dose (mg.h⁻¹)  | 1.0 [0.6 – 2.0]       | 1.0 [0.5 – 2.0]       | 0.676   |
| Prehospital AB administration | 80 (32%)              | 34 (22%)              | 0.023   |
| Prehospital duration (min)    | 70±31                 | 56±30                 | <10^{-3}|

| Prehospital final values      |                       |                       |         |
|-------------------------------|-----------------------|-----------------------|---------|
| Final SBP (mmHg)              | 110±25                | 92±25                 | <10^{-3}|
| Final DBP (mmHg)              | 63±19                 | 54±16                 | <10^{-3}|
| Final MBP (mmHg)              | 78±20                 | 67±18                 | <10^{-3}|
| Final HR (beats.min⁻¹)        | 104±25                | 110±26                | 0.010   |
| Final RR (movements.min⁻¹)    | 24 [19-32]            | 28 [21-35]            | 0.022   |
| Final pulse oximetry (%)      | 97 [95 – 99]          | 97 [93 – 99]          | 0.198   |
| Final body core temperature (°C) | 38.2 [36.9 – 39.0] | 38.1 [37.0 – 39.0] | 0.900   |
| Final Glasgow coma scale      | 15 [14-15]            | 15 [14-15]            | 0.149   |
| Final blood lactate (mmol.l⁻¹) | 4.4±3.6              | 4.5±3.7               | 0.823   |
| Delta blood lactate (mmol.l⁻¹) | 1.1±2.8              | 1.3±2.7               | 0.659   |
| Positive delta blood lactate  | 81 (32%)              | 34 (22%)              | 0.994   |
| Negative delta blood lactate  | 37 (15%)              | 17 (11%)              | 0.708   |

| Hospital parameters           |                       |                       |         |
|-------------------------------|-----------------------|-----------------------|---------|
| SOFA score                    | 7 [4-10]              | 8 [2-10]              | 0.501   |
| SAPS2 score                   | 56±21                 | 61±23                 | 0.115   |
| In-ICU length of stay (days)  | 5 [3-8]               | 4 [2-9]               | 0.326   |
| In-hospital length of stay (days) | 12 [7-20]        | 11 [6-20]             | 0.258   |

SBP: Systolic blood pressure, DBP: Diastolic blood pressure, MBP: Mean blood pressure, HR: Heart rate, RR: Respiratory rate, SI: Shock index, ICU: Intensive care unit, SOFA: Sequential Organ Failure Assessment, SAPS2: Simplified Acute Physiology Score 2nd version, COPD: Chronic Obstructive Pulmonary Disease, AB: Antibiotic therapy, min = minutes, negative delta SI = Initial SI — Final SI < 0, positive delta SI = Initial SI — Final SI > 0, delta Lactate = Lactate SI — Lactate SI, negative delta Lactate = Initial Lactate — Final Lactate < 0, positive delta Lactate = Initial Lactate — Final Lactate > 0.

Values in bold indicate a p-value < 0.05.
Results are expressed by adjusted Hazard ratio (HRa) with 95 percent confidence intervals [95 CI]. All tests were 2-sided with a statistically significant p-value of < 0.05. All analyses were performed using R 3.4.2 (http://www.R-project.org; the R Foundation for Statistical Computing, Vienna, Austria).

**Results**

**Population characteristics**

Among, the 406 patients analyzed with septic shock requiring action by the mICU, 268 patients (68%) were male, and the mean age was 69 ± 15 years old (Table 1). One-hundred and thirty-five patients (33%) were admitted to the ED and 271 patients (67%) admitted to the ICU after mICU intervention.

The median length of stay in a hospital was 12 [7–20] days and the median ICU length of stay was 5 [2–9] days (Table 1).

Pulmonary, digestive and urinary infections were the suspected cause of the SS in 42%, 25% and 17% of the cases, respectively (Table 1).

The 28-day overall mortality rate reached 29%.

No significant difference in the duration of the prehospital stage was observed between patients who survived and those who died on day-28 (64 ± 32 min vs 67 ± 31 min, p > 0.05; Table 1).

One-hundred and fourteen patients (28%) received prehospital antibiotic therapy, no significant difference was observed between patients who survived (n = 83, 29%) and those who died on day-28 (n = 31, 27%—p = 0.701) (Table 1). Among the 114 patients (28%) who received antibiotics prior to hospital admission, 74% were treated with 3rd generation cephalosporin, 42% with cefotaxime and 31% with ceftriaxone.

No significant difference was observed for norepinephrine dose between alive and deceased patients on day-28: 1.0 [0.5 – 2.0] vs 1.0 [0.7 – 2.0] mg.h⁻¹ respectively, p = 0.668 (Table 1).

Bivariate analysis reported a significant association between 28-day mortality and age, prehospital initial and final body core temperature, final prehospital respiratory rate, pulse oximetry, blood lactate, delta blood lactate, Glasgow coma scale, SOFA score, IGS-2 score and in-hospital length of stay (Table 1).

**Table 3** Comparison of predictive variable for 28-day mortality included in the propensity score before and after matching. Values are expressed as mean ± SD or number (%). d corresponds to the standard mean deviation

| Positive SI        | Before Matching | After Matching |
|--------------------|-----------------|---------------|
| n = 406            | n = 337         |               |
| n = 157            | n = 249         |               |
| n = 97             | n = 240         | 0.01          |
| **Age**            |                 |               |
| 68 ± 16            | 72 ± 14         |               |
| 69 ± 15            | 67 ± 16         | 0.92          |
| **Hypertension**   |                 |               |
| 65 (41%)           | 41 (42%)        | 0.16          |
| 65 (41%)           | 100 (42%)       |               |
| **COPD**           |                 |               |
| 25 (16%)           | 16 (16%)        | 0.16          |
| 31 (12%)           | 26 (11%)        |               |
| **Cancer**         |                 |               |
| 56 (35%)           | 74 (76%)        | 0.07          |
| 88 (35%)           | 40 (17%)        |               |
| **Diabetes mellitus** |               |               |
| 39 (25%)           | 22 (23%)        | 0.18          |
| 68 (27%)           | 72 (30%)        |               |
| **Chronic cardiac failure** |       |               |
| 36 (23%)           | 20 (21%)        | 0.15          |
| 33 (13%)           | 34 (14%)        |               |
| **Chronic renal failure** |            |               |
| 20 (13%)           | 17 (18%)        | 0.09          |
| 33 (13%)           | 26 (11%)        |               |
| **Immunodepression** |               |               |
| 43 (27%)           | 29 (30%)        | 0.55          |
| 77 (31%)           | 64 (27%)        |               |
| **Fluid expansion** |                 |               |
| 500 [500 – 1000]   | 750 [500 – 1200] | < 10⁻³      |
| 750 [500 – 1250]   | 750 [500 – 1025] |               |
| **Catecholamine**  |                 |               |
| 25 (16%)           | 29 (30%)        | 0.45          |
| 77 (31%)           | 62 (26%)        |               |
| **Antibiotic therapy** |             |               |
| 35 (22%)           | 25 (26%)        | 0.26          |
| 80 (32%)           | 77 (32%)        |               |
| **Prehospital duration** |           |               |
| 56 ± 30            | 60 ± 30         | 0.50          |
| 70 ± 31            | 66 ± 32         |               |
| **Hospital LOS**   |                 |               |
| 11 [6 – 21]        | 6 [2 – 12]      | < 10⁻³        |
| 12 [7 – 20]        | 15 [9 – 23]     |               |

PS Propensity score, LOS Length of stay, COPD Chronic obstructive pulmonary disease
0.1 ± 0.7. Two hundred and forty-eight patients (61%) had a positive delta SI, and 158 patients (39%) had a negative delta SI. Comparisons between patients with a positive and a negative delta SI are reported in Table 2.

Conversely, the mean initial blood lactate was 0.02 ± 0.04 mmol.l⁻¹.min⁻¹, the mean final blood lactate was 0.02 ± 0.05 mmol.l⁻¹.min⁻¹ and the mean delta blood lactate was 0.002 ± 0.1 mmol.l⁻¹.min⁻¹ (0.002 ± 0.1 for alive patients and 0.001 ± 0.1 mmol.l⁻¹.min⁻¹ for alive and deceased patients respectively, \( p = 0.215 \)). One-hundred and fifteen patients (28%) had a positive delta blood lactate, and 54 patients (13%) had a negative delta blood lactate.

After propensity score matching for positive SI, 337 patients: i.e., 240 negative delta SI and 97 positive delta SI were compared. Comparisons are reported in Table 3 and the absolute mean differences between subgroups after propensity score matching are depicted in Fig. 1.
Using Cox regression analysis on matched population, we observed a significant association between 28-day mortality and negative delta SI with an adjusted hazard ratio (HRa) of 1.88 [1.07–3.31] \((p = 0.03)\) as for positive delta SI: HRa = 0.53 [0.30–0.94] \((p < 10^{-3})\).

Figure 2 depicts Kaplan Meier curves after confounder adjustment for 28-day survival between positive delta SI and negative delta SI patients (Fig. 2).

Figure 3 represents Kaplan Meier curves after confounder adjustment for 28-day survival between positive delta lactate and negative delta lactate patients (Fig. 3).

**Discussion**

In this study, we observed a significant association between 28-day mortality and prehospital delta shock index. Negative prehospital delta SI is associated with a 1.9-fold 28-day mortality increase whereas positive prehospital delta SI is associated with a 1.9-fold 28-day mortality decrease among septic shock patients cared for by a mICU in the prehospital setting.

In order to reduce mortality related to sepsis, the World Health Assembly, the World Health Organization and the “SEPSIS-3” conference recommend early sepsis recognition and severity assessment, as key elements prior to early treatment initiation [7, 8].

In-hospital studies reported an association between septic shock patient poor outcome and clinical signs, biomarkers and severity scores, i.e., SOFA and IGS-2 [29, 30, 34–37]. Nevertheless, in the prehospital setting, only clinical signs and few biomarkers are available [12]. Elsewhere, the qSOFA score, which do not require biological criteria as opposed to SOFA and IGS-2, has been suggested for assessing sepsis severity, but its validity remains under debate [38–44]. To date, for sepsis severity assessment, blood lactate is the best biomarker [45, 46], available in the prehospital setting [28], associated with survival [15, 28, 47, 48]. In addition, lactate clearance represents an indirect tool for treatment effect assessment [7, 21], usable to guide sepsis resuscitation [7, 19, 20], although subjected to controversies [49, 50]. However,
blood lactate point of care testing is not worldwide available in the prehospital setting.

To bypass biomarkers’ limits, clinical signs have been proposed. On the one hand, capillary refill time and skin mottling score are associated with 28-day mortality [12]. SI, a simple clinical objective [51] tool, has an higher ability than hemodynamic physical signs (heart rate and blood pressure) for septic shock severity assessment [10] and is usable for early triage [13, 52]. To the best of our knowledges, this is the first study reporting a dynamic analysis of the SI in the prehospital stage of septic shock patients cared for by a mICU.

Nevertheless, the current study suffers from several limitations restricting the conclusions generalization. We cannot rule out a bias from misclassification of covariates, because data were collected from prehospital and in-hospital medical reports. Data accuracy may be compromised because data abstraction was collected by a single investigator [53]. Patients were only adults, consequently, the conclusions are not directly transposable to pediatric populations. Beta-blockers are widely prescribed, limiting SI increase despite an underlying illness. Despite no significant difference between alive and deceased patients, the fluid volume expansion is lower than recommended [7]. The study is retrospective; thus, no therapeutic goal (antibiotic therapy and/or hemodynamic optimization) was required for the mICU teams. In addition, the study focused on patients with septic shock, not on sepsis or other shock-etiologies. The external validity is affected by the specificity of the French prehospital EMS, based on SAMU and mICU intervention in the prehospital setting, contrary to others prehospital EMS organization based on paramedics.

Beyond these limitations, in a similar manner to lactate clearance, the ability of delta SI (i) to be an indirect tool for treatment effect assessment, and (ii) enabling sepsis resuscitation guiding, requires larger prospective trials.

**Conclusion**

Delta shock index in the prehospital stage of septic shock patients cared for by a mICU is significantly associated with 28-day mortality. A negative prehospital delta SI

---

![Kaplan Meier curves for 28 days survival](image_url)

**Fig. 3** Kaplan Meier curves of 28-day survival between patients with negative delta lactate and those with positive delta lactate.
is associated with a 1.9-fold 28-day mortality increase whereas positive delta SI is associated with a 1.9-fold 28-day mortality decrease. Further studies are needed to evaluate the ability of prehospital delta SI to assess hemodynamic optimization treatment effect assessment and its usefulness for sepsis resuscitation guiding during the prehospital setting.

**Authors’ information**

not applicable

**Abbreviations**

SS: Septic shock; SI: Shock index; mlICU: Mobile intensive care unit; HRa: Adjusted hazard ratio; ED: Emergency department; ICU: Intensive care unit; SAMU: Urgent Medical Aid Service; SMUR: Mobile Emergency and Resuscitation Service; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MAP: Mean arterial pressure; HR: Heart rate; SpO2: Pulse oximetry; RR: Respiratory rate; GCS: Glasgow coma scale; LOS: Length of stay; SOFA: Sequential Organ Failure Assessment; SAPS 2: Simplified Acute Physiology Score; SMD: Standardized mean deviation.

**Acknowledgements**

None

**Author contributions**

Conceptualization: Romain Jouffroy, Papa Gueye. Methodology: Romain Jouffroy. Data curation: Romain Jouffroy, Basile Gilbert, Léa Thomas, Emmanuel Bloch-Laine, Patrick Ecollan, Vincent Bounes, Josiane Boularan, Papa Gueye. Supervision: Romain Jouffroy, Papa Gueye. Investigation: Romain Jouffroy, Papa Gueye. Writing- Reviewing and Editing: Romain Jouffroy, Basile Gilbert, Léa Thomas, Emmanuel Bloch-Laine, Patrick Ecollan, Vincent Bounes, Josiane Boularan, Papa Gueye. Benoît Vivien. All authors read and approved the final manuscript.

**Funding**

none

**Availability of data and materials**

The dataset analyzed during the current study is not publicly available because their containing information that could compromise the privacy of research participants but are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the French Society of Anaesthesia and Intensive Care ethics committee on 2017, December 12\(^{th}\). The French Society of Anaesthesia and Intensive Care ethics committee waived the need of informed consent.

**Consent for publication**

Not applicable.

**Competing interests**

none author has any competing interests. All methods were performed in accordance with the relevant guidelines and regulations.

**Author details**

1Intensive Care Unit, Ambroise Paré Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France. 2IRMES - Institute for Research in Medicine and Epidemiology of Sport, INSEP, Paris, France. 3INSERM U-1018, Centre de Recherche en Epidémiologie Et Santé Des Populations - U1018 INSERM, Paris Saclay University, Paris, France. 4Université de Paris, 7329 Paris, EA, France. 5Intensive Care Unit, Anaesthesiaology, SAMU, Necker Enfants Malades Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France. 6Department of Emergency Medicine, University Hospital of Toulouse, SAMU 31, Toulouse, France. 7Hôpital d'Instruction Des Armées Bégin, Paris, France. 8Emergency Department, Cochin Hospital, Paris, France & Emergency Department, SMUR, Hôtel Dieu Hospital, Paris, France. 9Intensive Care Unit, SMUR, Pitie Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013 Paris, France. 10Centre Hospitalier Intercommunal Castres-Mazamet, Paris, France. 11SAMU 972 CHU de Martinique Pierre Zobda Quitman Hospital, Fort-de-France Martinique, France.

Received: 3 October 2021 Accepted: 13 April 2022

Published online: 19 May 2022

**References**

1. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsagarakis T, Schlattmann P. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Resp Crit Care Med. 2016;193(3):259–72.

2. Gaiëski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41(5):1167–74.

3. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kieyvan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–11.

4. Busani S, Damiani E, Cavazzuti I, Donati A, Girardis M. Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta-analysis of the clinical effectiveness. Minerva Anestesiol. 2016;82(5):559–72.

5. Luhr R, Cao Y, Soderquist B, Cajander S. Trends in sepsis mortality over time in randomised sepsis trials: a systematic literature review and meta-analysis of mortality in the control arm, 2002–2016. Crit Care. 2019;23(1):241.

6. Sakr Y, Elia C, Mascia L, Barbers B, Cardellino S, Livigni S, et al. Epidemiology and outcome of sepsis syndromes in Italian ICUs: a multicentre, observational cohort study in the region of Piedmont. Minerva Anestesiol. 2013;79(9):993–1002.

7. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–10.

8. World Health Organization. Improving the prevention, diagnosis and clinical management of sepsis. 2017. Available at: https://www.who.int/activities/improving-the-prevention-diagnosis-and-clinical-manageme nt-of-sepsis.

9. Pottecher T, Calvat S, Dupont H, Durand-Gasselin J, Gerbeaux P, workgroup SS. Haemodynamic management of severe sepsis: recommendations of the French Intensive Care Societies (SFAR/SRLF) Consensus Conference, 13 October 2005, Paris, France. Crit Care. 2006;10(4):311.

10. Guignis FW, Jones L, Esma R, Weiss A, McCurdy K, Fereira J, et al. Managing sepsis: Electronic recognition, rapid response teams, and standardized care save lives. J Crit Care. 2017;40:296–302.

11. Aligöwer MBC. Schock index Deutsche Medizinische Wodenschrift. 1967;46:1–10.

12. Jouffroy R, Saade A, Tourjert JP, Gueye P, Bloch-Laine E, Ecollan P, et al. Skin mottling score and capillary refill time to assess mortality of septic shock since pre-hospital setting. Am J Emerg Med. 2019;37(4):664–71.

13. Jouffroy R, Pierre Tourjert J, Gueye P, Bloch-Laine E, Ecollan P, et al. Skin mottling score and capillary refill time in randomised sepsis trials: a systematic literature review and meta-analysis of mortality in the control arm, 2002–2016. Crit Care. 2019;23(1):241.

14. Bakker J, Coffemis M, Leon M, Gris P, Vincent JL. Blood lactate levels are superior to oxygen-derived variables in predicting outcome in human septic shock. Chest. 1991;99(4):956–62.

15. Jones AE. Lactate clearance for assessing response to resuscitation in severe sepsis. Acad Emerg Med. 2013;20(8):844–7.

16. Bao L, Zhang M, Yan P, Wu X, Shao J, Zheng R. Retrospective analysis of the value of arterial blood lactate level and its clearance rate on the prognosis of septic shock patients. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27(1):38–42.
17. Nguyen HB, Kuan WS, Bateh M, Shirkhanda P, Mahadevan M, Li CH, et al. Outcome effectiveness of the severe sepsis resuscitation bundle with addition of lactate clearance as a bundle item: a multi-national evaluation. Crit Care. 2011;15(5):R229.

18. Tian HH, Han SS, Lu CJ, Wang T, Li Z, Hao D, et al. The effect of early goal lactate clearance rate on the outcome of septic shock patients with severe pneumonia. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2012;24(1):42–5.

19. Pan J, Peng M, Liao C, Hu X, Wang A, Li X. Relative efficacy and safety of early lactate clearance-guided therapy resuscitation in patients with sepsis: A meta-analysis. Medicine (Baltimore). 2019;98(8):e14453.

20. Pyroo SM, Lee J, Lee YS, Lee JH, Lim KS, Huh JW, et al. Lactate Level Versus Lactate Clearance for Predicting Mortality in Patients With Septic Shock Defined by Sepsis-3. Crit Care Med. 2018;46(6):e489–95.

21. Shapiro NI, Howell MD, Talmor D, Nathanson LA, Libon A, Wolfe RE, et al. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med. 2005;45(5):524–8.

22. Jouffroy R, Gilbert B, Tournier JP, Bloch-Laine E, Ecollan R, Bounes V, et al. Impact of Prehospital Antibiotic Therapy on Septic Shock Mortality. Prehosp Emerg Care. 2020:1–8.

23. Jouffroy R, Saade A, Muret A, Philippe P, Michaloux M, Carli P, et al. Fluid resuscitation in pre-hospital management of septic shock. Am J Emerg Med. 2018;36(10):1754–8.

24. Adnet F, Lapostolle F. International EMS systems: France. Resuscitation. 2011;82(8):1041–50.

25. Jouffroy RGB, Gueye P, Tourtier JP, Bloch-Laine E, Li CH, et al. Use of prehospital lactate clearance as a bundle item: a multi-national evaluation. J Emerg Med. 2017;25(1):56.

26. April MD, Donaldson C, Tannenbaum LI, Moore T, Aguirre J, Dubin A, et al. Prehospital lactate clearance is associated with reduced mortality in patients with septic shock. Am J Emerg Med. 2017;35(10):1474–9.

27. Jouffroy R, Leguillier T, Gilbert B, Tournier JP, Bloch-Laine E, Ecollan P, et al. Prehospital lactate clearance is associated with reduced mortality in patients with septic shock. JAMA. 2019;321(7):654–64.

28. Askim A, Moser F, Gustad LT, Stene H, Gundersen M, Asvold BO, et al. Poor performance of quick-SOFA (qSOFA) score in predicting severe sepsis and mortality – a prospective study of patients admitted with infection to the emergency department. Scand J Trauma Resusc Emerg Med. 2017;25(1):56.

29. Koyama S, Yamaguchi Y, Goko K, Nakayama I, Ueda S. Use of prehospital qSOFA in predicting-in-hospital mortality in patients with suspected infection: A retrospective cohort study. PLoS ONE. 2019;14(5):e0216560.

30. Lane J, Lin S, Scales DC. Classification versus Prediction of Mortality Risk using the SIRS and qSOFA Scores in Patients with Infection Transported by Paramedics. Prehosp Emerg Care. 2019:1–8.

31. Silcock DJ, Corfield AR, Staines H, Rooney KD. Superior performance of National Early Warning Score compared with quick Sepsis-related Organ Failure Assessment Score in predicting adverse outcomes: a retrospective observational study of patients in the prehospital setting. Eur J Emerg Med. 2019;26(6):433–9.

32. Hernandez G, Ospina-Tascon GA, Dubin A, Damiani LP, Estenssoro E, Dubin A, et al. Emergency department septic shock patient mortality with refractory hypotension vs hyperlactatemia: A retrospective cohort study. Am J Emerg Med. 2019;37(5):801–7.

33. Ait-Oufella H, Bige N, Boelle PY, Pichereau C, Alves M, Bertinchamp R, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–10.

34. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270(24):2957–63.

35. Gearing RE, Mian IA, Barber J, Ickowitz A. A methodology for conducting retrospective chart review research in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2006;15(3):126–34.

36. Austen PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399–424.

37. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(23):3083–107.

38. Ait-Oufella H, Bige N, Boelle PY, Pichereau C, Alves M, Bertonchamp R, et al. Capillary refill time exploration during septic shock. Intensive Care Med. 2014;40(7):958–64.

39. Koyama S, Yamaguchi Y, Goko K, Nakayama I, Ueda S. Use of prehospital qSOFA in predicting-in-hospital mortality in patients with suspected infection: A retrospective cohort study. PLoS ONE. 2019;14(5):e0216560.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.